Gilead Sciences (NASDAQ:GILD) Updates FY 2026 Earnings Guidance

Gilead Sciences (NASDAQ:GILD) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of -1.050–0.650 for the period, compared to the consensus earnings per share estimate of 8.650. The company issued revenue guidance of $30.0 billion-$30.4 billion, compared to the consensus revenue estimate of $30.2 billion.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on GILD. UBS Group boosted their price target on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a report on Monday, January 26th. Truist Financial boosted their price target on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Wells Fargo & Company boosted their price target on Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Citigroup boosted their price target on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $157.35.

Gilead Sciences Stock Down 1.6%

Shares of GILD stock traded down $2.24 during midday trading on Thursday, reaching $134.06. 7,909,571 shares of the stock were exchanged, compared to its average volume of 6,772,439. Gilead Sciences has a 1 year low of $95.29 and a 1 year high of $157.29. The company’s 50 day moving average is $139.87 and its two-hundred day moving average is $132.79. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The firm has a market cap of $166.40 billion, a PE ratio of 19.80, a price-to-earnings-growth ratio of 1.77 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the business earned $1.90 EPS. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts predict that Gilead Sciences will post 8.62 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total value of $463,290.00. Following the sale, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at $25,910,110.97. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total value of $4,324,320.00. Following the completion of the sale, the insider directly owned 120,288 shares in the company, valued at approximately $18,577,278.72. This represents a 18.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 63,000 shares of company stock worth $9,238,250. Company insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GILD. Vermillion & White Wealth Management Group LLC raised its stake in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at $26,000. Swiss RE Ltd. purchased a new stake in Gilead Sciences during the 4th quarter valued at $31,000. Mcguire Capital Advisors Inc. purchased a new stake in Gilead Sciences during the 4th quarter valued at $43,000. Finally, Acumen Wealth Advisors LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at $46,000. 83.67% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.